Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | CCR3 | P51677 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | BACE1 | P56817 | 3/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776772 | 0.89 | ACHE (0.58) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL42500 | 0.89 | ACHE (0.58) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL2775677 | 0.89 | ACHE (0.58) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL8315434 | 0.83 | ACHE (0.71) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL4849743 | 0.83 | POLB (0.64) | ALDH1A1HTR2A | |
| SCHEMBL7363662 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL2010139 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL4257757 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD2DRD4 | |
| SCHEMBL4700697 | 0.81 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1CXCR4MEN1KMT2A | |
| SCHEMBL242970 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3002287-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | NAT DEFENSE MEDICAL CENTER (TW) | 2018-01-31 | — | — | EP | claimed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| EP-3002287-A1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | National Defense Medical Center (TW) | 2016-04-06 | — | — | EP | claimed |
| US-8927717-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-01-06 | — | — | US | claimed |
| EP-1865963-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | Acadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| US-20060217370-A1 | Compounds useful for the treatment and prevention of pain and screening methods therefor | ACADIA PHARMACEUTICALS INC. | 2006-09-28 | — | — | US | claimed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2001023392-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-05 | — | — | WO | claimed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-5066643-A | Enzyme inhibitors, protease and esterase, hypotensive agents, congestive heart failure | SANDOZ LTD. (CH) | 1991-11-19 | — | — | US | claimed |
| US-4746649-A | Diamino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1988-05-24 | — | — | US | claimed |
| EP-0186977-A2 | Renin-inhibitory dipeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-07-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | ACHE 18/4885SIGMAR1 3525/4885CCR3 1071/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | ACHE 98/4885SIGMAR1 502/4885CCR3 3159/4885 |
| US-20060217370-A1 | Compounds useful for the treatment and prevention of pain and screening methods therefor | ACHE, OPRL1, OPRK1 | ACHE 1/4885SIGMAR1 81/4885CCR3 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.